Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PTC Therapeutics Achieves BMI1 Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

PTC Therapeutics Achieves BMI1 Milestone

PTC Therapeutics, through its Wellcome Trust collaboration, has identified a chemical series of molecules that penetrates the blood-brain barrier in animal models and reduces levels of BMI1, a protein linked to drug-resistant cancers.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PTC Therapeutics, through its Wellcome Trust collaboration, has identified a chemical series of molecules that penetrates the blood-brain barrier in animal models and reduces levels of BMI1, a protein linked to drug-resistant cancers. The milestone triggers a $2.2 million payment to PTC.

The Wellcome Trust awarded PTC $5.4 million to support the development of drugs that target BMI1 back in June 2010. PTC identified the lead chemical series using its screening technique GEMS. The goal of the program is to identify a drug candidate for the treatment of chemotherapy-resistant cancers.

“We are pleased to reach this first milestone in our collaboration with the Wellcome Trust on schedule,” said Stuart W. Peltz, Ph.D., president and chief executive officer of PTC Therapeutics. “We believe the therapeutic potential of a small-molecule inhibitor of BMI1 production is very significant. This milestone will support chemistry optimization efforts toward our next major goal of declaring a development candidate.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics